Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Bupropion + Naltrexone Clear all

Conditions: Binge-Eating Disorder, Obesity
Interventions: Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment); Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Smoking, Nicotine Dependence
Interventions: Naltrexone, Bupropion; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Heart Failure, Methamphetamine Use Disorder
Interventions: MUD Management (contingency management +/- adjunctive MUD pharmacotherapy), HF GDMT management; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets); Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Methamphetamine Dependence
Interventions: placebo, Naltrexone and Bupropion SR; Other · Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obesity
Interventions: Naltrexone-Bupropion Combination; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Cocaine Use Disorders
Interventions: Bupropion; Drug
Lead sponsor: Craig Rush; Other
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Binge-Eating Disorder
Interventions: Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity
Interventions: Intervention Control, Counselling, Contrave, Contrave and Counseling; Behavioral · Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Scottsbluff, Nebraska

Conditions: Obesity
Interventions: Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, fMRI scan; Drug · Other
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Upton, New York

Conditions: Abdominal Wall Hernia
Interventions: Preoperative Weight Management Program; Other
Lead sponsor: Benjamin T. Miller; Other
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Chicago, Illinois • Cleveland, Ohio

Conditions: Obesity & Overweight, Cardiometabolic Health Indicators
Interventions: GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose, Resistance exercise regimen, Lifestyle/nutrition counseling; Drug · Behavioral
Lead sponsor: Jing Luo; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Methamphetamine Use Disorder
Interventions: Naltrexone: Vivitrol®, Placebo (PLB) Injectable, Bupropion: Wellbutrin XL®, Placebo (PLB) Oral; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Minneapolis, Minnesota + 5 more

Conditions: Nicotine Dependence, Overweight, Obesity
Interventions: NB32, Ancillary therapy; Drug · Behavioral
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Encino, California • Los Alamitos, California • Newport Beach, California

Conditions: Obesity, Overweight
Interventions: Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy; Drug · Behavioral
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 34
States / cities: Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more

Conditions: Obesity, Overweight
Interventions: NB32, PBO, Weight Management Program; Drug · Behavioral
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 45 Years and older
Enrollment: 8,910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 224
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more

Conditions: Type 2 Diabetes, Obesity
Interventions: Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat; Other · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions: Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Placebo, Ancillary therapy; Drug · Behavioral
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 53
States / cities: Fairhope, Alabama • Peoria, Arizona • Phoenix, Arizona + 46 more

Conditions: Binge Eating Disorder
Interventions: Naltrexone and bupropion combination, Pill Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity
Interventions: Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity
Interventions: Not listed
Lead sponsor: Currax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31,889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Brentwood, Tennessee

Conditions: Obesity
Interventions: Naltrexone-Bupropion (NB) Combination, Placebo; Drug
Lead sponsor: Currax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 140
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 111 more

Conditions: Obesity, Overweight
Interventions: Behavioral Weight Loss (BWL), Early Responder: BWL continued, Early Non-responder: BWL continued with medication added; Behavioral · Combination Product
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity, Cardiovascular Diseases
Interventions: Naltrexone HCl/Bupropion HCl ER, Placebo; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 139
States / cities: Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more

Search by objective public record fields.

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment

Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain

Methamphetamine Use Disorder Support in Heart Failure Pilot Study

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study

Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence

Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

Preoperative Weight Loss for Open Abdominal Wall Reconstruction

Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo

Individualized Obesity Pharmacotherapy

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Weight Regain Treatment Post-Bariatric Surgery

Naltrexone/Bupropion Cardiovascular Outcomes Study